Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Outlines International Safety, Compliance Initiatives At RAPS Meeting

This article was originally published in The Gray Sheet

Executive Summary

FDA is planning a series of initiatives and new hires over the next two years to help improve import safety and address the agency's growing globalization challenges

You may also be interested in...



People In Brief

CDRH compliance chief to retire: Tim Ulatowski will retire from FDA at the end of the year, the veteran agency staffer announced in an April 12 memo to staff. Ulatowski said he made the decision before the new FDA administration came on board last year. An opening for the CDRH Office of Compliance director position was posted April 12 and FDA will review candidates and select a replacement "over the next few weeks," Ulatowski predicts. A smooth transition is important given CDRH's ambitious agenda for the coming years, he said (1"The Gray Sheet" April 5, 2010). "A break in permanent leadership for maybe a few months while all this is occurring would not be helpful," Ulatowski said in the memo. Once the new director is hired, Ulatowski will shift to a temporary advising role until his retirement. He has been with FDA since 1974 and with the Office of Compliance since 2003

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel